Roxane Laboratories’s bid to knock out Prometheus Laboratories's patent covering its Lotronex (alosetron) product has been successful after the US Court of Appeals for the Federal Circuit affirmed that it is invalid.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Roxane Laboratories; Prometheus Laboratories; Lotronex; irritable bowel syndrome; US Court of Appeals for the Federal Circuit; generics; ANDA